Jupiter Neurosciences (NASDAQ:JUNS) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen downgraded shares of Jupiter Neurosciences (NASDAQ:JUNS) to a strong sell rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Jupiter Neurosciences Stock Down 9.5%

Jupiter Neurosciences stock opened at $5.10 on Friday. Jupiter Neurosciences has a 52-week low of $4.76 and a 52-week high of $137.96. The company has a market cap of $2.45 million, a P/E ratio of -0.25 and a beta of 1.98. The business has a 50-day simple moving average of $14.34 and a two-hundred day simple moving average of $27.58.

Jupiter Neurosciences (NASDAQ:JUNS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($4.50) earnings per share for the quarter, missing the consensus estimate of ($3.75) by ($0.75). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.23 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Allen Capital Group LLC bought a new stake in Jupiter Neurosciences during the fourth quarter valued at about $31,000. Geode Capital Management LLC lifted its holdings in Jupiter Neurosciences by 27.8% in the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares in the last quarter. Yorkville Advisors Global LP purchased a new position in Jupiter Neurosciences in the 4th quarter worth approximately $135,000. Finally, Vestor Capital LLC lifted its holdings in Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares in the last quarter.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.